Annexon
Update in progressANNX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Annexon is a clinical‑stage biopharmaceutical company that discovers and develops medicines for inflammatory diseases. Its lead program, Tanruprubart, a full‑length monoclonal antibody, is in Phase 3 for Guillain‑Barré syndrome, has completed Phase II for Huntington’s disease, and is in Phase 2a for ALS. ANX007 (Fab) is in Phase 3 for geographic atrophy; ANX1502 is an oral small‑molecule in Phase 1 for autoimmune indications; ANX009 (C1q Fab) is in Phase I for lupus nephritis. Founded 2011, based in Brisbane, California.
Company score
- Sentiment
- 0.27
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!